RealPharma: Conversations with Pharma Pathfinders

When Healthcare Policy Incentives Backfire: 340B, Hospital Pricing, MFN, and Drug Affordability with Deborah Williams
Healthcare policies are often evaluated by what they are intended to accomplish. But what happens when the incentives created by those policies produce very different results?

In this episode of RealPharma, Ian Wendt and Dr. Na-Ri Oh speak with longtime health policy expert Deborah Williams about the unintended consequences embedded in the U.S. healthcare system—from hospital reimbursement and industry consolidation to the 340B Drug Pricing Program, biosimilars, most-favored-nation pricing, and pharmaceutical innovation.

Deborah argues that healthcare policy must be judged not by its stated purpose, but by the behaviors, financial incentives, and measurable outcomes it creates. The discussion examines why transparency alone may not lower healthcare costs, how hospital systems use their political and economic influence, and why policies designed to improve affordability can sometimes contribute to higher prices.

The conversation also explores the practical and constitutional uncertainties surrounding most-favored-nation drug pricing, the Trump administration’s GARD, GLOBE, and GENEROUS models, and the potential downstream effects of pricing reform on research, development, manufacturing, and patient access.

Topics Discussed

Why healthcare policy should be evaluated by results rather than intentions

The history and limitations of diagnosis-related groups, or DRGs

Why MACRA has failed to create an effective physician payment system

Whether healthcare price transparency can meaningfully reduce costs

The effects of hospital consolidation and certificate-of-need laws

Why hospital systems have become so politically difficult to challenge

Indiana’s effort to cap hospital prices relative to Medicare rates

The widening divide between large health systems and rural hospitals

How nonprofit hospitals deploy capital and justify tax-exempt status

The role of hospital employment in local political influence

Why 340B purchasing incentives can favor higher-priced branded products

How 340B spreads may undermine biosimilar adoption

Whether 340B savings are reaching vulnerable patients

Alternatives to funding safety-net and uncompensated-care services through drug discounts

Why policymakers may need to separate hospital support from pharmaceutical pricing

The rationale behind most-favored-nation drug pricing

Whether European countries are likely to pay more for pharmaceuticals

How Medicaid best-price rules affect commercial contracting

The relationship between direct-to-consumer pricing and 340B exposure

GARD, GLOBE, and GENEROUS drug-pricing models

The legal and constitutional questions surrounding mandatory drug rebates

Pharmaceutical manufacturing reshoring and national economic policy

How interest rates and global reimbursement policies affect drug development

The need to measure the quality—not merely the quantity—of pharmaceutical innovation

Why every healthcare payment system has both intended and unintended consequences

Key Takeaways
Policy intentions do not guarantee beneficial outcomes
Even carefully designed reimbursement systems can produce distortions once stakeholders respond to the incentives. Deborah emphasizes that policymakers must continuously measure what happens after implementation rather than assuming a program is working because its goals are admirable.

Transparency is necessary, but not sufficient
Publishing hospital prices may help patients and purchasers compare costs, but transparency has limited value when every available option is still unaffordable. Meaningful reform may also require addressing hospital concentration, market power, and state certificate-of-need restrictions.

Hospitals possess considerable economic and political power
Large health systems are often among the biggest employers in a congressional district or state. That employment base, combined with campaign contributions and community influence, makes hospital payment reform politically difficult—even when prices and capital spending appear difficult to justify.

The 340B program can create incentives that conflict with affordability
The discussion examines how hospitals may earn substantial spreads between the discounted acquisition cost of a drug and the amount ultimately reimbursed. Those spreads can influence product selection, encourage use of higher-priced brands, and weaken the competitive position of lower-cost biosimilars.

Safety-net funding should be tied to services society wants to support
Rather than indirectly subsidizing hospitals through drug-pricing spreads, Deborah suggests that policymakers consider more direct support for uncompensated care, emergency services, obstetrics, psychiatric care, and other socially valuable services.

Most-favored-nation pricing remains highly uncertain
MFN policies may be politically attractive because Americans pay more for many medicines than patients in other developed countries. However, other countries may be unwilling or unable to increase their spending, leaving manufacturers to absorb much of the financial impact in the United States.

Drug-pricing rules interact in complicated ways
Best-price requirements, 340B discounts, Medicare reimbursement, direct-to-consumer models, and international reference pricing cannot be evaluated in isolation. A change in one area can cascade through the rest of the pharmaceutical pricing system.

Innovation should be measured by scientific and clinical value
Deborah argues that policy analysis should move beyond simply estimating how many drugs might be lost under a pricing reform. The more important question is whether policies reduce the development of first-in-class therapies, novel mechanisms, and clinically meaningful advances.

Episode Summary
In this episode of Real Pharma, hosts Na-Ri Oh and Ian Wendt sit down with Kristiaan Rawlings, Executive Director at EPM Scientific, to unpack what is really happening in the biopharma talent market right now. From the surprising resurgence of market access hiring to the growing influence of AI in recruiting and candidate preparation, this conversation explores the forces reshaping commercial talent strategy in 2026. The group also digs into salary inflation, title compression, M&A-driven hiring shifts, hybrid work expectations, and why communication skills and executive presence may matter more than ever.

What We Cover

Why market access has re-emerged as one of the hottest hiring areas in biopharma

How companies are responding to policy shifts, competition, and launch pressure

What the current K-shaped hiring market means for candidates in high-demand vs. lower-demand functions

Why specialists in forecasting, analytics, and insights may need to broaden their skill sets

How AI is affecting interviews, candidate prep, and recruiting workflows

The continued importance of presentation skills, executive presence, and storytelling

How M&A activity is influencing hiring, retention packages, and future job movement

What’s happening with salary growth, especially at the director, senior director, and VP levels

Why hybrid work is still the norm and fully remote roles remain limited

What candidates should know before making a move in 2026

Key Takeaways
Biopharma hiring is not following a single trend. Some functions are seeing intense demand and rising compensation, while others are consolidating under broader roles. Kristiaan explains that market access, select commercial operations roles, and experience in competitive therapeutic areas are commanding a premium right now. At the same time, he notes that professionals who can combine technical skill with strong communication and leadership presence are consistently outperforming others in the interview process.

The episode also highlights a more nuanced view of AI: it is not simply replacing jobs, but it is changing how work gets done. Used well, AI can improve recruiting efficiency, candidate prep, and search precision. Used poorly, it can make candidates sound generic, underprepared, or overly scripted.

🧠 Episode Summary
What if we’ve been thinking about cancer all wrong?

In this deeply personal and paradigm-shifting episode of RealPharma, hosts Dr. Na-Ri Oh and Ian Wendt sit down with Dr. Christopher Gregg—neuroscientist, entrepreneur, and stage 4 cancer patient—to explore a bold new vision for cancer care.

Dr. Gregg shares how his own diagnosis sparked a radical rethink of oncology: moving away from the “war on cancer” mindset toward managing it as a chronic, controllable condition. Drawing inspiration from agriculture, AI, and evolutionary biology, he introduces the concept of “algorithms as drugs”—dynamic, data-driven treatment strategies designed to outmaneuver resistance.

This conversation blends cutting-edge science with raw human experience, offering a hopeful and pragmatic roadmap for the future of precision medicine.

🔑 Key Topics Covered

Why curing cancer may not always be the best goal—and what to aim for instead

The concept of adaptive therapy and managing cancer like a chronic disease

What elephants, farmers, and pests can teach us about treatment resistance

The limitations of today’s drug development and clinical trial systems

“Algorithms as drugs” and the future of programmable medicine

How AI, smartphones, and behavioral data can unlock scalable precision care

The role of value-based care models in accelerating innovation

Dr. Gregg’s personal journey living 7+ years with stage 4 cancer

Building Storyline Health, Primordial AI, and Uncharted Health

The importance of patient agency—and the risks of unguided experimentation

 

 
🚀 Why This Episode Matters
Cancer care is at an inflection point. While billions are spent developing new drugs, Dr. Gregg argues that the real breakthrough may come from how we use the drugs we already have.

By combining AI, real-time patient data, and systems thinking, this approach could dramatically extend lives, reduce costs, and make care more human-centered.

🔗 Learn More

Explore Dr. Gregg’s free masterclass: Uncharted Health

Follow developments from Storyline Health and Primordial AI

Stay tuned for upcoming clinical applications of algorithm-driven care

🎧 About the Guest
Dr. Christopher Gregg is a Professor of Neurobiology and Human Genetics at the University of Utah, a leading researcher in genomics and brain science, and a biotech entrepreneur. His work spans neuroscience, AI, and precision medicine—and is deeply informed by his personal experience living with metastatic cancer.

The Opioid Reckoning (Part 2): Litigation, Accountability, and the Fight for Justice with Paul T. Farrell Jr.

In Part 2 of our deep dive into the opioid crisis, hosts Dr. Na-Ri Oh and Ian Wendt continue their conversation with Paul T. Farrell Jr., the West Virginia attorney who helped lead the historic national opioid litigation.

This episode moves beyond the legal strategy discussed in Part 1 and explores the human toll, the documentary that captured the battle, the controversial trial outcome, and the surprising legal reversal years later. It’s a story of perseverance, public health accountability, and the long arc of justice.

🎬 From Courtroom to Documentary
Paul shares the unexpected origin story behind the PBS documentary The Bitter Pill, directed by Clay Tweel. What began as a filmmaker casually attending a hearing soon turned into a seven-year chronicle of the opioid litigation, capturing the rise of a local lawsuit in Huntington, West Virginia into a nationwide legal movement.

The documentary highlights not only the legal fight but also the devastating real-world impact of the opioid epidemic on families, healthcare workers, and communities.

⚖️ The Trial That Shook the Case
A major focus of the episode is the Cabell County trial, the first major test of the legal strategy that ultimately helped drive national settlements.

Paul explains how:

The case became the bellwether trial for thousands of similar lawsuits.

A national settlement framework complicated the ability to settle locally.

The federal judge ultimately ruled against the plaintiffs on legal grounds—even as similar arguments succeeded in other jurisdictions.

For Paul and his team, the ruling felt like a devastating setback after years of work.

💰 The $50 Billion National Settlement
Despite the loss in the bellwether trial, the broader litigation resulted in nearly $50 billion in settlements with pharmaceutical manufacturers, distributors, and pharmacies.

Paul explains the goals behind the settlement:

Transparency around how opioid pills were distributed across the U.S.

Accountability for the systemic failures that fueled the epidemic

Funding for opioid abatement programs, rather than compensation for individual claims

In West Virginia, settlement funds were allocated through a unique structure that created the West Virginia First Foundation, a statewide public-private trust designed to ensure funds are used specifically to combat addiction and support recovery programs.

🔄 A Stunning Legal Reversal
The documentary originally ends on a bleak note after the Cabell County loss. But the story didn’t end there.

In October 2025, the Fourth Circuit Court of Appeals reversed the trial court’s decision, reopening the case and giving Cabell County another opportunity to argue its claims.

For Paul, the decision brought a sense of vindication after years of uncertainty and reignited the fight for accountability.

🧠 Has the System Changed?
The episode closes with a broader discussion about whether the opioid crisis could happen again.

Paul reflects on changes across the healthcare ecosystem:

Greater scrutiny and transparency in medical research and publishing

Stronger safeguards for pharmacists and prescription monitoring

Increased attention to controlled substance distribution practices

But he also warns that the incentives in healthcare and pharmaceuticals remain powerful—and vigilance will be essential.

💡 Final Reflections
When asked what sustains him through years of litigation, setbacks, and public scrutiny, Paul points to faith, community, and the people who show up along the journey at the right moments.

It’s a fitting close to a story that began with one lawsuit in a small Appalachian city—and grew into one of the largest public health litigations in U.S. history.

🎧 In This Episode

The origin and filming of The Bitter Pill documentary

Inside the Cabell County bellwether trial

Why the national opioid settlement unfolded the way it did

The structure and purpose of opioid abatement funding

The 2025 appellate reversal that revived the case

Whether the healthcare system has truly changed

👥 Guest
Paul T. Farrell Jr.
Attorney and lead counsel in the Cabell County opioid litigation, which helped catalyze the nationwide opioid settlements.

The Opioid Reckoning (Part 1): Paul Farrell Jr. on Litigation, Accountability, and the System That Failed

West Virginia has had the highest drug overdose death rate in the United States for over a decade. In a state with fewer than 2 million people, 780 million prescription opioids were distributed in just six years.

For Paul Farrell Jr., a Huntington, West Virginia native and mass tort attorney, those numbers weren’t abstract statistics. They were neighbors. Friends. Family members.

In Part 1 of this two-part episode, hosts Na-Ri Oh and Ian Wendt sit down with Paul to unpack how the largest civil litigation in American history — the opioid multidistrict litigation (MDL 2804) — came together, and how it reshaped the conversation around corporate accountability in the pharmaceutical supply chain.

This is not just a legal story. It’s a story about systems failure — across manufacturers, distributors, regulators, policymakers, and healthcare stakeholders — and what happens when transparency finally forces a reckoning.

In This Episode

Growing up in Huntington, WV as the opioid crisis escalated

The investigative journalism that exposed 780 million pills — and the moment Paul decided to act

What “public nuisance” law is — and why it became the legal breakthrough strategy

The role of distributors as the “choke point” in the opioid supply chain

How 3,000+ cases consolidated into the largest MDL in U.S. history

Why abatement — not just financial damages — became central to the settlement strategy

Internal company communications that revealed troubling attitudes toward affected communities

The intersection of regulation, enforcement, and corporate responsibility

How transparency and subpoena power changed the trajectory of the crisis

Why This Conversation Matters
For those working in pharma, healthcare, commercialization, policy, compliance, or distribution, this episode challenges us to examine difficult questions:

Where does responsibility truly lie in a complex healthcare ecosystem?

What happens when financial incentives distort oversight?

And how do we prevent the next Pandora’s box from opening?

This episode sets the foundation for a deeper conversation about accountability, culture, regulation, and reform.

Coming Next Week: Part 2
There was simply too much to cover in one episode.

In Part 2, we’ll explore:

The evolution of the litigation and key tipping points

The role of state attorneys general and settlement frameworks

The ongoing PBM litigation

The documentary The Bitter Pill

And what lasting change should look like for the industry

Make sure to subscribe so you don’t miss it.